Dr Sindhuja Kadambi speaks to ecancer about enzalutamide with 5-alpha-reductase inhibitors (5-ARI) for older patients with castration-sensitive systemic prostate cancer.

This study evaluates the effects on fatigue and physical well-being for older adults with prostate cancer who are treated with enzalutamide and 5-alpha-reductase inhibitors.

Geriatric assessments link fatigue to declines in physical health.

The study emphasises the safety of second-generation anti-androgens and the importance of ongoing patient monitoring.

It also highlights the frailty of caregivers, stressing the need for increased support for them.